Medical Devices Rules 2017: Govt proposes faster licence approvals for manufacturers
Synopsis
India's Health Ministry has proposed trimming manufacturing licence timelines for medical devices — cutting Class B approvals by 25 days and high-risk Class C/D approvals by 15 days — under draft amendments to the Medical Devices Rules, 2017. The move introduces stage-wise regulatory milestones without relaxing quality or safety standards, and is open for public comment via the Official Gazette.
Key Takeaways
The Ministry of Health and Family Welfare published a draft notification on 28 June 2025 proposing amendments to the Medical Devices Rules, 2017 .
Class B device manufacturing licence timelines proposed to fall from 140 days to 115 days .
Class C and Class D device licence timelines proposed to reduce from 105 days to 90 days .
Draft introduces stage-wise defined timelines covering scrutiny, audits, compliance verification, and licence issuance.
Existing quality, safety, and performance standards for medical devices will remain unchanged.
Stakeholders can submit comments via the Official Gazette and the CDSCO website within the prescribed period.
The Ministry of Health and Family Welfare on 28 June 2025 proposed amendments to the Medical Devices Rules, 2017 aimed at cutting approval timelines for manufacturing licences across device categories, in a move to boost ease of doing business and accelerate patient access to quality medical products in India.
A draft notification has been published in the Official Gazette and on the website of the Central Drugs Standard Control Organisation (CDSCO), inviting public comments from stakeholders before the changes are finalised.
Proposed Timeline Reductions by Device Class
India's medical device regulatory framework classifies products into four risk-based tiers — Class A, Class B, Class C, and Class D — with Class D carrying the highest risk profile.
Under the proposed changes, the timeline for granting manufacturing licences for Class B devices — which include everyday diagnostic tools such as blood pressure monitors, pulse oximeters, and hypodermic needles — would be reduced from 140 days to 115 days, a cut of 25 days.
For higher-risk Class C and Class D devices — encompassing cardiac stents, hip implants, knee implants, and other orthopaedic implants — the proposed approval window would shrink from 105 days to 90 days, a reduction of 15 days.
What the Draft Amendments Introduce
Beyond headline timeline cuts, the draft proposes clearly defined milestones for every stage of the licensing process, including application scrutiny, audits by notified bodies, compliance verification, and final licence issuance. According to the ministry, these stage-wise timelines are intended to enhance transparency, predictability, and efficiency within the regulatory framework.
Crucially, the ministry has stated that existing quality, safety, and performance standards for medical devices will remain unchanged — the amendments target procedural speed, not regulatory thresholds.
Why This Matters for India's Medical Device Sector
India's medical devices market has grown rapidly in recent years, yet domestic manufacturers have long flagged prolonged approval cycles as a bottleneck that pushes up costs and delays product launches. Faster licences could reduce time-to-market for Indian-made devices and, in turn, improve availability of affordable, quality-assured products for patients.
This comes amid the government's broader push to position India as a global medical device manufacturing hub, with dedicated clusters in states such as Andhra Pradesh, Telangana, Himachal Pradesh, and Uttar Pradesh already operational or under development. Notably, the amendments align with the Centre's ongoing efforts to streamline business regulations across the healthcare and pharmaceutical sectors.
Next Steps for Stakeholders
The draft notification is currently open for public comment, with stakeholders — including manufacturers, industry associations, and healthcare providers — invited to submit their views within the prescribed period. The final amendments will be notified after the consultation process concludes. Industry bodies are expected to respond with feedback on whether the proposed reductions go far enough, given that some manufacturers have previously called for single-window clearance systems.
Point of View
15 days for Class C and D — are incremental rather than transformative. India's medical device manufacturers have long argued that approval bottlenecks are structural, not merely procedural, and that a stage-wise timeline alone does not address single-window clearance gaps or the capacity constraints at notified bodies conducting audits. The more consequential question is whether CDSCO has the bandwidth to honour the new deadlines without simply shifting the backlog downstream. If enforcement of the timelines is not accompanied by a parallel expansion of regulatory capacity, the reform risks being a calendar change on paper rather than a genuine acceleration in practice.
NationPress
28 Jun 2026
Frequently Asked Questions
What changes has the government proposed to medical device manufacturing licences?
The Ministry of Health and Family Welfare has proposed reducing approval timelines for manufacturing licences under the Medical Devices Rules, 2017. Class B device licences would be cleared in 115 days instead of 140, while Class C and Class D device licences would be processed in 90 days instead of 105.
Which medical devices fall under Class B, Class C, and Class D?
Class B covers low- to moderate-risk devices such as blood pressure monitors, pulse oximeters, and hypodermic needles. Class C and Class D include higher-risk products like cardiac stents, hip implants, knee implants, and other orthopaedic implants.
Will quality and safety standards for medical devices be relaxed under the new rules?
No. The ministry has explicitly stated that existing quality, safety, and performance standards will remain intact. The amendments target only the procedural speed of the licensing process, not the regulatory thresholds devices must meet.
How can stakeholders provide feedback on the proposed amendments?
The draft notification is available in the Official Gazette and on the CDSCO website. Stakeholders — including manufacturers, industry associations, and healthcare providers — can submit comments and suggestions within the prescribed consultation period before the amendments are finalised.
Why is the government pushing for faster medical device approvals?
Prolonged approval cycles have been a longstanding concern for domestic manufacturers, raising costs and delaying product launches. Faster licences are intended to improve ease of doing business and accelerate patient access to quality-assured, affordable medical devices, in line with the Centre's broader push to make India a global medical device manufacturing hub.
